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Abstract
Background: To compare the adverse events after initiation of nevirapine-based ART among HIV-
infected patients who did not receive fluconazole (group A), received fluconazole 400 mg/week
(group B), and received fluconazole 200 mg/day (group C).
Methods: A retrospective cohort study was conducted among HIV-infected patients who began
NVP-based ART between December 2003 and September 2004. Patients were followed up for 6
months. Clinical hepatitis, elevated aspartate aminotransferase (AST) and alanine aminotransferase
(ALT) (> 3 times from baseline), and skin rashes were studied.
Results: There were 686 patients; 225, 392, and 69 patients in group A, B, and C, respectively.
Baseline characteristics including age, previous opportunistic infections, use of antituberculous
drugs, and baseline aminotransferase levels among the three groups were similar. Group C had a
higher proportion of men (p = 0.016). Baseline median (IQR) CD4 cell counts were 85 (21–159),
18 (7–48), and 16 (5–35) cell/mm3 in group A, B, and C, respectively (p < 0.001). Of 2/225 (0.9%),
4/392 (1.0%), and 0/69 (0%) patients in group A, B, and C developed clinical hepatitis (p = 0.705).
There were no significant difference of elevated AST or ALT among the three groups (p > 0.05).
By logistic regression, receiving fluconazole was not predictive of clinical hepatitis, elevated
aminotransferase, or skin rashes. At 6 months after initiating NVP, 174 (77.3%) patients in group
A, 309 (78.8%) patients in group B, and 58 (84.1%) patients in group C remained on NVP.
Conclusion: Initiation of NVP-based ART among Thais with advance HIV disease receiving
fluconazole is safe and well-tolerated. nevirapine should not be contraindicated for patients
receiving fluconazole for treatment or prophylaxis of cryptococcosis.
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Highly active antiretroviral therapy (HAART) has been
widely used for the treatment of human immunodefi-
ciency virus (HIV) infected patients with successful
immune restoration and reductions in morbidity and
mortality [1,2]. However, access to antiretroviral therapy
for HIV-infected patients in resource-limited countries is
still a major obstacle [3,4]. HIV-infected patients in these
areas often presented with advanced HIV disease. Nevi-
rapine (NVP) is a non-nucleoside reverse transcriptase
inhibitor (NNRTI) that has shown efficacy even in
advanced HIV disease [5-8]. NVP-based HAART has been
widely used in the resource-limited countries because of
its efficacy, relative low cost, and availability. Addition-
ally, NVP is part of two of the four World Health Organi-
zation-recommended generic combinations for the 3 × 5
program in resource-limited countries [9]. NVP-related
adverse events particularly skin rashes and hepatotoxicity
have been well recognized as the limitation of NVP use
[10-12]. NVP-associated skin rashes usually appear after
one to four weeks of treatment [10]. The risk of hepatotox-
icity is greatest in the first six weeks of treatment and con-
tinues through 18 weeks of treatment [13].
Fluconazole is a commonly used for the prophylaxis and
treatment of cryptococcosis in HIV-infected patients. Flu-
conazole 400 mg/day has been used as standard therapy
for treatment of cryptocoocal meningitis after completion
of two weeks of amphotericin B [12]. Fluconazole 200
mg/day is used for secondary prophylaxis until immune
reconstitution occurs with HAART [14]. Fluconazole 400
mg/week is recommended for primary prophylaxis
among HIV-infected patients with CD4 cell count <100
cells/mm3 in Thailand and some developing countries
because of a high prevalence of cryptococcosis and the evi-
dence of a survival benefit [15]. Nonetheless, the potential
drug-drug interaction between NVP and fluconazole is a
major concern. Both drugs can induce cytochrome P450
isoenzymes in the liver [16-18]. Geel et al recently
reported that fluconazole significantly raised plasma NVP
levels and may cause serious hepatotoxicity [19]. So far,
there have not been enough data or any recommenda-
tions to adjust NVP dosage for the concomitant use of
both drugs in order to avoiding adverse events. A previous
study demonstrated that genetic disposition may play a
role in NVP hypersensitivity reactions [20]. There is little
data of safety and tolerability for concurrent use of NVP
and fluconazole in Asian populations. We therefore con-
ducted this retrospective cohort study to compare the fre-
quencies of hepatotoxicity and skin rashes among HIV-
infected patients who received fluconazole and subse-
quently received NVP-based HAART regimens.
Methods
A retrospective cohort study was conducted among
antiretroviral-naïve HIV-infected patients who began a
NVP-based HAART regimens between December 2003
and September 2004 at Bamrasnaradura Institute, Minis-
try of Public Health, Nonthaburi, Thailand. Inclusion cri-
teria were as follows: (1) HIV-infected patients > 15 years
of age, (2) naïve to antiretroviral therapy, (3) began
antiretroviral therapy with a NVP-based HAART regimen,
(4) used NVP 200-mg once-daily lead-in dose, prior to
escalation to 200 mg twice daily. Each eligible patient was
classified into one of three groups according to whether
he or she received fluconazole or not and the different
dosages of fluconazole as follows: not received flucona-
zole (group A), received fluconazole 400 mg/week (group
B), and received fluconazole 200 mg/day (group C). All
patients were followed for 6 months after initiating NVP-
based HAART. The primary objective was to compare the
frequency of clinical hepatitis among the three groups.
The secondary objectives of interest were to compare the
frequencies of elevated aspartate aminotransferase (AST)
and alanine aminotransferase (ALT) > three times from
baseline at six months after initiation of NVP and to com-
pare the frequencies skin rashes among the three groups.
The patients' clinical statuses including clinical hepatitis
and skin rashes were assessed monthly by the attending
physician. Liver functions test was performed at 6 months
after initiating NVP in case of no evidence of hepatitis.
Clinical hepatitis was defined as symptomatic hepatitis
and either AST or ALT elevated > five times the upper limit
of normal. Signs and symptoms of hepatitis may include
anorexia, malaise, jaundice, nausea/vomiting, hepatome-
galy, and hepatic tenderness. Skin rash was determined by
medical record of skin reactions including diffuse ery-
thematous or maculopapular rash, urticarial rash, serum
sickness-like reaction, Stevens-Johnson syndrome, and
toxic epidermal necrolysis.
Mean (± standard deviation, SD), median (interquartile
range, IQR) and frequencies (%) were used to describe
patients' characteristics in each treatment groups. Chi-
square test and Kruskal-Walis test were used to compare
categorical and continuous variables among the treatment
groups, respectively. Logistic regression was used to deter-
mine predicting factors for each adverse event of interest.
The possible risk factors were entered into the model of
binary logistic regression. Spearman correlation was use
to study the relationship between skin rashes and clinical
hepatitis, skin rashes and aminotransferase levels. All
analyses were performed using SPSS program version
11.5. A P value less than 0.05 was considered statistically
significant. The study was approved from the institute
review board.Page 2 of 7
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A total of 686 patients were eligible and included in the
study. Of 686 patients; 225, 392, and 69 patients were
classified into group A, B, and C, respectively. The baseline
characteristics of patients prior to initiation of HAART are
described and compared among the three groups as
shown in Table 1. Baseline characteristics including age,
previous major opportunistic infections (OIs), use for
antituberculous drugs therapy, baseline AST and ALT, and
baseline HIV RNA prior to HAART were not different
among the three groups. Group C patients had a greater
proportion of men than the other groups (p = 0.016).
Group B and group C patients had more advanced HIV
disease [i.e., lower body weight (p = 0.008), lower base-
line CD4 cell counts prior to initiation of HAART (p <
0.001), and higher proportion receiving co-trimoxazole(p
< 0.001)] than patients in group A.
One hundred and four of 255 (40.8%) in group A, 188 of
392 (48.0%) in group B, and 36 of 69 (52.2%) in group C
had AST testing at 6 months after initiating NVP. Seventy
one of 255 (29.4%), 95 of 392 (24.2%), and 22 of 69
(31.9%) in corresponding groups had ALT testing at 6
months after initiating NVP. The prevalence of patients
who developed adverse events including clinical hepatitis,
AST and ALT increase > 3 times from baseline, and skin
rashes are shown in Table 2. The prevalence of clinical
hepatitis, elevated AST, and elevated ALT were not differ-
ent among the three groups (p > 0.05). There was a
significant difference among the groups in the prevalence
of skin rashes (p = 0.016).
Results of logistic regression analysis indicated that receiv-
ing anti-tuberculous drugs was a significant predictor of
clinical hepatitis (p = 0.025) (Table 3). Gender, body
weight, baseline CD4 cell counts, or receiving fluconazole
were not predictive of clinical hepatitis. Logistic regression
analyses of models including gender, body weight, base-
line CD4 cell count, receiving anti-tuberculous drugs, and
receiving fluconazole, were not significant predictors of
elevated AST > 3 times from baseline (χ2 (5, N = 328) =
3.72, p = 0.592) and elevated ALT > 3 times from baseline
(χ2 (5, N = 188) = 7.26, p = 0.298). Logistic regression
analysis of skin rashes indicated that receiving anti-tuber-
culous drugs was a significant predictor of skin rashes
Table 1: Baseline characteristic of 686 patients receiving NVP-based HAART.
Baseline characteristics Not receiving 
fluconazole
Receiving fluconazole P value
(n = 225) 400 mg/week (n = 392) 200 mg/day (n = 69)
Gender: Male 116 (51.6%) 213 (54.3%) 49 (71.0%) 0.016
Female 109 (48.4%) 179 (45.7%) 20 (29.0%)
Age, years, mean ± SD 36.0 ± 7.5 35.0 ± 7.4 34.7 ± 8.03 0.200
Weight, kg., mean ± SD 54.9 ± 10.6 52.3 ± 10.0 51.4 ± 8.7 0.008
Previous opportunistic infections, patients (%)
Any major opportunistic infections 53 (23.6%) 120 (30.6%) 24 (34.8%) 0.368
Tuberculosis 32 (14.2%) 64 (16.3%) 17 (24.6%) 0.124
PCP 31 (13.8%) 47 (12.0%) 8 (11.6%) 0.787
Histoplasmosis 3 (1.3%) 1 (0.3%) - 0.190
Penicilliosis 3 (1.3%) 0 (0.0%) - 0.046
Toxoplasmosis - 5 (1.3%) - 0.151
MAC 2 (0.9%) 2 (0.5%) - 0.669
Concurrent medication
Cotrimoxazole 176 (78.2%) 363 (93.3%) 57 (82.6%) < 0.001
Antituberculous drugs 47 (20.9%) 82 (20.9%) 22 (31.9%) 0.095
Baseline CD4 cell count, cell/mm3, median (IQR) 85 (21–159) 18 (7–48) 16 (5–35) < 0.001
Baseline % CD4, median (IQR) 7 (2–11) 2 (1–5) 2 (1–5) < 0.001
Baseline plasma HIV RNA, 207,500 270,000 169,000 0.095
copies/ml, median (IQR) (68,375–549,500) (118,000–545,000) (76,750–415,000)
Baseline AST, U/L, median (IQR) 31 (23–46.5) 32 (25–53.2) 34 (24–53) 0.358
Baseline ALT, U/L, median (IQR) 23 (17–39) 28 (17–45) 32 (17–49.5) 0.177
Baseline TB, mg/dl, median (IQR) 0.5 (0.4–0.65) 0.5 (0.4–0.7) 0.5 (0.4–0.8) 0.843Page 3 of 7
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or receiving fluconazole were not predictive of skin rashes.
The results of correlation analyses show that there was no
correlation between skin rashes and clinical hepatitis (rs =
0.026, p = 0.491), skin rashes and AST (rs = 0.003, p =
0.948), or skin rashes and ALT (rs = 0.034, p = 0.637). The
tolerability of NVP-based HAART is shown in Table 5.
Regarding NVP-associated skin rashes, the majority (>
90%) of patients developed diffuse maculopapular
rashes. Only 1 of 25 patient in group A and 2 of 26
patients in groups B developed Steven-Johnson syn-
dromes. Nine patients died, 1 in group A and 8 in group
B. The majority of patients died from opportunistic
infections (i.e., 2 cryptococcosis, 2 bacterial pneumonitis,
1 Mycobacterium avium complex infection, and 3 wasting
syndromes). No patient died from hepatitis.
Discussion
In the present study, we have shown that the prevalence of
clinical hepatitis and AST and ALT elevation 6 months
after initiating HAART among HIV-infected patients who
concurrently received NVP and fluconazole were not dif-
ferent from those who received NVP- based HAART with-
out fluconazole. These findings suggest that
administration of NVP-based HAART regimens in HIV-
infected patients who receive fluconazole dose not
increase the risk of hepatotoxicity. The prevalence of clin-
ical hepatitis and aminotransferase elevations in our study
was lower than that reported in studies conducted in Afri-
can HIV-infected patients [19,20]. There may be several
Table 2: Frequency of adverse events among the three groups.
Adverse events Not receiving fluconazole Receiving fluconazole P value
(n = 225) 400 mg/week (n = 392) 200 mg/day (n = 69)
Clinical hepatitis 2/225 (0.9%) 4/392 (1.0%) 0/69 (0%) 0.705
Elevated AST > 3 times from baseline 3/104 (2.9%) 5/188 (2.7%) 3/36 (8.3%) 0.192
Elevated ALT > 3 times from baseline 6/71 (8.5%) 7/95 (7.4%) 2/22 (9.1%) 0.938
Skin Rash 23/225 (10.2%) 27/392 (6.9%) 0/69 (0%) 0.016
Table 3: Logistic regression of possible risk factors and clinical hepatitis
Risk factors Odd Ratios 95% confidence interval P value
Female gender 1.25 0.21–7.49 0.809
Body weight 1.08 0.98–1.17 0.076
Baseline CD4 cell count 0.99 0.97–1.01 0.352
Receiving anti-tuberculous drugs 7.42 1.27–43.31 0.026
Receiving fluconazole 1.12 0.18–6.90 0.901
Receiving Cotrimoxazole 0.84 0.21–5.44 0.675
Table 4: Logistic regression of possible risk factors and skin rashes.
Factors Odd Ratios 95% confidence interval P value
Female gender 1.26 0.67–2.39 0.470
Body weight 1.02 0.98–1.05 0.347
Baseline CD4 cell count 1.00 0.99–1.01 0.873
Receiving anti-tuberculous drugs 2.96 1.04–8.47 0.043
Receiving fluconazole 1.56 0.79–3.08 0.201
Receiving Cotrimoxazole 1.21 0.68–2.91 0.594Page 4 of 7
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study had very low CD4 cell counts (i.e., 97% had CD4
cell counts < 200 cells/mm3 and 80% had CD4 cell counts
< 100 cells/mm3). High CD4 cell count is a predictor of
hepatotoxicity [11,19]. Second, there was a higher propor-
tion of men in our study than the previous studies
[17,18]. CD4 cell counts are more predictive of hepatotox-
icity among men than women (i.e., men who have a CD4
cell counts > 400 cells/mm3 are at a greater risk of hepatitis
than women with CD4 cell counts > 250 cells/mm3)
[13,21]. Third, our study included Asians, which was dif-
ferent from the previous study [11,17,18]. Sanne et al
reported that African women may have an increased like-
lihood of hepatotoxicity [20]. The previous studies dem-
onstrate that there are differences in drug and alcohol
metabolism that may be related to genetic or environmen-
tal factors (e.g., differences in diet and protein intake) [22-
24]. There is little data on differences in NVP metabolism
based on genetic disposition.
While logistic regression analyses in the present study
show that receiving fluconazole was not predictive for any
adverse events, receiving anti-tuberculous drugs was sig-
nificantly predictive for both clinical hepatitis and skin
rashes. The patients in our large cohort had overall 16% of
concurrent tuberculosis and the results from the regres-
sion analyses can demonstrate this important issue. These
findings point out that concurrent concomitant use of
NVP and anti-tuberculous drugs may a cause of more con-
cern. We suggest to closely monitoring liver function test
in patients with concomitant use of NVP and anti-tuber-
culous drugs. Further well-designed prospective study is
needed.
Regarding NVP-associated skin rashes, the overall preva-
lence in the present study was similar to previous study in
Thai patients with advanced HIV disease [25]. The inci-
dence of NVP-associated skin rashes in the patients who
received Fluconazole was lower than the other groups.
This may be explained by the lower CD4 cells count in this
group. As the previous studies have demonstrated that
persons with a higher baseline CD4 cell counts are likely
to develop rash from NVP [26]. Given there was no corre-
lation between skin rashes and clinical hepatitis or ele-
vated aminotransferase, these two entities of adverse
events may need different approaches for monitoring and
management.
Overall about 80% of the patients in our cohort contin-
ued on NVP-based HAART at six months. Although all
patients were initiated with NVP 200-mg once-daily lead-
in dose prior to escalation to 200 mg twice daily, skin rash
was still the major adverse event led to discontinuation of
NVP-based HAART. The previous studies using short-
course prednisolone were failed to prevent NVP-associ-
ated skin rashes [26,27]. The further study to minimize
this major limitation is needed.
NVP-based HAART is a common regimen which widely
used for treatment of HIV-infected patients in resource-
limited countries due to its affordability. Until the other
options are more accessible, NVP-based HAART is still a
key regimen to scale up treatment of HIV in resource-lim-
ited countries. Our study may provide the safety data of
concomitant use of NVP and fluconazole and support the
use of NVP in patients receiving fluconazole for treatment
or prophylaxis of cryptococcal diseases.
The limitation of the present study is the nature of retro-
spective study that patients' clinical status may be under-
reported. First, not all patients had been checked for
aminotransferase level during the first 6 months. Only
328 and 188 patients had been checked for AST and ALT
levels, respectively. However, we had analyzed the demo-
graphics and adverse events between patients who had
and did not have AST or ALT levels and found that there
Table 5: Tolerability of NVP-based HAART among the three groups.
Tolerability outcomes Not receiving fluconazole Receiving fluconazole P value
(n = 225) 400 mg/week (n = 392) 200 mg/day (n = 69)
On NVP-based HAART at six months 174 (77.3%) 309 (78.8%) 58 (84.1%) 0.532
Reasons of discontinuation 0.448
Adverse events 26 (11.5%) 29 (7.4%) 3 (4.3%)
Skin rashes 25/26 (96.2%) 26/29 (89.7%) 3 of 3 (100.0%)
Hepatotoxicity 1/26 (2.8%) 3/29 (10.3%) -
Death 1 (0.4%) 8 (2.0%) -
Loss to follow-up 20 (8.9%) 39 (9.9%) 7 (10.1%)
Refer 4 (1.8%) 7 (1.8%) 1 (1.4%)Page 5 of 7
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have data of plasma NVP level in this cohort due to retro-
spective nature. However, Dailly et al reported that there
was no association between plasma NVP level and hepa-
totoxicity [28]. Ultimately, the present study did not
assess patients who initiated NVP while received flucona-
zole 400 mg/day.
Conclusion
In summary, receiving of fluconazole for treatment or
prophylaxis of cryptococcosis does not increase the risk of
hepatotoxicity, elevated aminotransferase, or skin rashes
from NVP. Initiation of NVP-based HAART among HIV-
infected patients receiving fluconazole is safe and well-tol-
erated. Use of anti-tuberculous drugs is predictive of clin-
ical hepatitis and skin rashes. Initiation of NVP-based
HAART in HIV-infected patients receiving anti-tubercu-
lous needs closely monitoring and prompt management.
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